Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence

NCT04013672 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Glioblastoma

Interventions

DRUG: Pembrolizumab
DRUG: SurVaxM
DRUG: Sargramostim
DRUG: Montanide ISA 51

Sponsor

David Peereboom